Microbiotica today announced that it will join the microbiome panel at this year’s BIO-Europe®, taking place in Copenhagen between 5-7 November.
Cambridge, UK, 30 October 2018 – Microbiotica, a leading player in microbiome-based therapeutics, today announced that it will join the microbiome panel at this year’s BIO-Europe®, taking place in Copenhagen between 5-7 November.
Mike Romanos, CEO of Microbiotica, will participate in the Microbiome and the Implication on Other Therapeutic Areas along with panellists from Enterome, Ferring Pharmaceuticals, Health Opportunities GmbH, Sorbonne University and Seventure Partners, Microbiotica’s newest investor. The panel will take place in Room C2 between 1.30-2.30pm on Monday 5 November.
The BIO-Europe 2018 partnering event is expected to draw over 4,000 industry attendees for three days of high-level networking, representing more than 2,000 companies from over 60 countries.
Microbiotica has had a transformational year in 2018, signing collaborative deals with Genentech and the University of Adelaide, as well as securing additional investment.
- ENDS -
Notes To Editors
About Microbiotica
Microbiotica was established in 2016 to develop and commercialise ground-breaking research into the role of the human microbiome in health and disease and its application to medicine conducted in the Host-Microbiotica Interactions Laboratory (“HMIL”) at the Sanger Institute. The Company was founded by Dr Mike Romanos, Dr Trevor Lawley and Professor Gordon Dougan, FRS. Microbiotica is based at the Wellcome Genome Campus in Cambridge, UK, with offices in the Biodata Innovation Centre and laboratories in the Sanger Institute. It has a strategic collaboration with Genentech, a member of the Roche Group, in the field of inflammatory bowel disease (IBD) as well as with University of Adelaide to develop a defined product for ulcerative colitis.
Microbiotica has attracted £12m in equity investment from Cambridge Innovation Capital, IP Group plc and Seventure Partners.
For more information, please visit www.microbiotica.com, LinkedIn and Twitter.
About Microbiotica’s platform
The Microbiotica platform comprises the world’s leading microbiome Culture Collection and linked Reference Genome Database that enable unprecedented precision of gut bacterial identification The Company is adding to this at a very rapid rate through its industrial culturing and sequencing pipeline, providing the best available representation of clinical trial samples for strain-level identification of bacteria. The complex datasets that arise from such studies are analysed using AI techniques to discern microbiome signatures linked to phenotype. The availability of the physical Culture Collection enables biological evaluation of bacteria in proprietary translational models including humanised microbiome mouse models.
About the Microbiome
Recognition of the importance of the microbiome, the body’s trillions of resident bacteria, represents a paradigm-shift in our understanding of its impact on human health and disease. This creates major opportunities in the diagnosis and treatment of a wide range of disease including enteric infections, autoimmune disorders, metabolic disorders, cancer and neurological disease.
